Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis

Fifty-nine patients with amyotrophic lateral sclerosis participated in a 12-month, double-blind crossover trial. The patients were given either levamisole 150 mg or placebo in identical tablets once a week orally, and a rating of neurologic signs and symptoms was recorded on monthly visits. The patients were crossed over at 6 months. Levamisole had no effect on the rate of score decline in the 20 patients who completed the trial.